Phase 2
Completed N=39
Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing Spondylitis
Source: ClinicalTrials.gov NCT01109940 ↗Enrolled (actual)
39
Serious AEs
12.8%
Results posted
Jun 2021
Primary outcomePrimary: Number of Participants Reported Adverse Events (AE's) — 21; 6; 6; 3 Participants
Summary
This study is designed as an extension study to the proof-of-concept trial CAIN457A2209 in patients with moderate to severe ankylosing spondylitis and aims to provide continuous treatment with AIN457 for patients in the core trial, to obtain safety and tolerability information. The study will address the evaluation of efficacy following doses of Intravenous infusion (IV) of 3 mg/kg AIN457 given every 4 weeks over a period initially up to 6 months (Part 1) and based on the risk/benefit balance of AIN457 in ankylosing spondylitis a decision was taken to continue dosing for another 6 month period (Part 2).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants Reported Adverse Events (AE's) |
21; 6; 6; 3 | — |
| SECONDARY Number of Participants Reported Positive Antibodies for Secukinumab |
0; 0; 0; 0; 0; 0 | — |
| SECONDARY Total Interleukin (IL)- 17A Concentration in Blood at Steady-State |
— | — |
| SECONDARY Maximum (Peak) Observed in Serum at Steady-State (Cmax,ss) |
10.5; 10.6; 11.3; 17.1 | — |
| SECONDARY Minimum (Trough) Observed in Serum at Steady State (Cmin,ss) |
4.73; 15.0; 0.0428; 27.1 | — |
Eligibility Criteria
Inclusion Criteria
- Patients who took part and completed in the core CAIN457A2209 study
- Patients who discontinued the core study due to unsatisfactory therapeutic effect at their Visit 14 (Week 16) or later could enter the extension study within 3 weeks of completing the study discontinuation visit of the core study, provided that at their discontinuation visit they fulfilled either one of the criteria below. Patients who did not enter the extension study within 3 weeks of completing the study discontinuation visit of the core study, were required to come for an additional baseline visit (Visit 17) and were required to fulfill either one of the criteria below:
- No improvement (compared with the core study baseline) in two out of the following four domains: patient global assessment, pain, BASFI and the mean of the two morning stiffness questions from the BASDAI. OR
- Deterioration (compared with the core study baseline) in one of the four domains (deterioration defined as >=20% worsening and an absolute worsening of >=1 unit)
Exclusion Criteria
- Patients for whom continued treatment with AIN457 is not considered appropriate by the treating physician.
- Patients who were non-compliant or who demonstrated a major protocol deviation in the core CAIN457A2209 study.
- Patients who discontinued from the core CAIN457A2209 study before Visit 14 (Week 16), and patients who completed the core study
- Pregnant or lactating women
- Presence of active infection
- Positive PPD or HIV test in patients where repeated testing was deemed appropriate due to their risk profile
Other protocol-defined inclusion/exclusion criteria may apply
Data sourced from ClinicalTrials.gov (NCT01109940). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.